SPRY
ARS Pharmaceuticals, Inc.
Company Overview
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
SectorHealthcare
IndustryBiotechnology
Market Cap$400.8M
Last DividendNone
Employees195
CEODonn Casale
Websitehttps://ars-pharma.com
Valuation
Current Price$4.03
Fair Value?$000.00
Valuation?No valuation
Current PE ?N/Aⓘ
Hist. PE ?N/Aⓘ
EPS (TTM) ?-2.17
Forward EPS Growth ?—
Historical Growth ?4.11%
Equity, FCF, Long Term Debt, Net Profit, and Shares Outstanding history charts are available on the Pro plan for just $9.99/month.Sign in to unlock Pro
Price?
EPS?
Revenue?
Equity?
ProAvailable on the Pro plan
Free Cash Flow?
ProAvailable on the Pro plan
Long Term Debt?
ProAvailable on the Pro plan
Net Profit?
ProAvailable on the Pro plan
Shares Outstanding?
ProAvailable on the Pro plan
Last updated: 10/23/2026, 10:57:01 PM